Drug Profile
Eptacog alfa - Novo Nordisk
Alternative Names: Activated recombinant human factor VII; Factor VIIa; NiaStase; NN 007; NovoSeven; NovoSeven RT; NovoSeven RT with MixProT; NovoSeven with pre-filled syringe; Novostase; Recombinant factor VIIa; rFVIIaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer Novo Nordisk
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Factor VIIa stimulants; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Factor VII deficiency; Haemophilia; Thrombasthenia
- Registered Postpartum haemorrhage
- Phase III Haemorrhage
Most Recent Events
- 21 Feb 2023 Registered for Postoperative haemorrhage in European Union (IV) , prior to February 2023
- 22 Apr 2022 The EMA's Committee for Medicinal Products for Human Use recommended approval of eptacog alfa for severe postpartum haemorrhage in European Union
- 22 Apr 2022 Interim efficacy and adverse events data from a clinical trial in postoperative haemorrhage released by Novo Nordisk